The performance of companies tied to the drug's legacy presents a challenging investment picture . While the initial boom generated substantial returns , generic competition have significantly diminished revenue. Investing in associated pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving patient changes,